BIRC5 and neoplasm: Interestingly, mutation studies of Survivin identified that its cytoplasmic localisation results from its active export from the nucleus and imply that the biological characteristics of Survivin itself within tumour cells might account for the clinical properties of the tumour (Rodriguez et al, 2002).